These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33276238)

  • 1. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.
    Hua LH; Hersh CM; Tian F; Mowry EM; Fitzgerald KC
    Mult Scler Relat Disord; 2021 Jan; 47():102637. PubMed ID: 33276238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
    Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
    Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
    J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
    Hadjimichael O; Vollmer T; Oleen-Burkey M;
    Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes.
    Diržiuvienė B; Mickevičienė D
    Mult Scler Relat Disord; 2022 Mar; 59():103558. PubMed ID: 35123292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice.
    Baldassari LE; Nakamura K; Moss BP; Macaron G; Li H; Weber M; Jones SE; Rao SM; Miller D; Conway DS; Bermel RA; Cohen JA; Ontaneda D; McGinley MP
    Mult Scler Relat Disord; 2020 Feb; 38():101525. PubMed ID: 31759186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis in the elderly: a retrospective cohort study.
    Zinganell A; Göbel G; Berek K; Hofer B; Asenbaum-Nan S; Barang M; Böck K; Bsteh C; Bsteh G; Eger S; Eggers C; Fertl E; Joldic D; Khalil M; Langenscheidt D; Komposch M; Kornek B; Kraus J; Krendl R; Rauschka H; Sellner J; Auer M; Hegen H; Pauli FD; Deisenhammer F
    J Neurol; 2024 Feb; 271(2):674-687. PubMed ID: 37855871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab.
    Karampampa K; Gyllensten H; Friberg E; Murley C; Kavaliunas A; Hillert J; Olsson T; Alexanderson K
    BMJ Open; 2023 May; 13(5):e067516. PubMed ID: 37192793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing relapsing remitting multiple sclerosis patients burdened with hypertension, hyperlipidemia, and asthma.
    Sorensen A; Conway DS; Briggs FBS
    Mult Scler Relat Disord; 2021 Aug; 53():103040. PubMed ID: 34058603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
    Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.